Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the spanish rheumatology society lupus registry (RELESSER) with emphasis on complete versus incomplete lupus differences

Medicine (United States)

Volumn 94, Issue 1, 2015, Pages e267-

  Rúa Figueroa, Íñigo ^a   Richi, Patricia ^b   López Longo, Francisco Javier ^c   Galindo, María ^d   Calvo Alén, Jaime ^e   Olivé Marqués, Alejandro ^f   Loza Santamaría, Estíbaliz ^g   Vicente, Sabina Pérez ^g   Erausquin, Celia ^h   Tomero, Eva ⁱ   Horcada, Loreto ^j   Uriarte, Esther ^k   Sánchez Atrio, Ana ^l   Rosas, José ^m   Montilla, Carlos ⁿ   Fernández Nebro, Antonio ^o   Rodríguez Gómez, Manuel ^p   Vela, Paloma ^q   Blanco, Ricardo ^r   Freire, Mercedes ^s   Silva, Lucía ^t   Díez Álvarez, Elvira ^u   Ibáñez Barceló, Mónica ^v   Zea, Antonio ^w   Narváez, Javier ^x   Martínez Taboada, Víctor ^r   Marenco, José Luis ^y   De Castro, Mónica Fernández ^z   Fernández Berrizbeitia, Olaia ^aa   Hernández Beriain, José Ángel ^ab   Gantes, Marian ^ac   Hernández Cruz, Blanca ^ad   Pérez Venegas, José J ^ae   Pecondón, Ángela ^af   Marras, Carlos ^ag   Carreira, Patricia ^d   Bonilla, Gema ^ah   Torrente, Vicente ^ai   Castellví, Iván ^aj   Alegre, Juan ^ak   Moreno, Mireia ^al   Raya, Enrique ^am   De La Peña, Paloma García ^an   Vázquez, Tomás ^m   Aguirre, Ángeles ^ao   Quevedo, Víctor ^ap   Pego Reigosa, José M ^aq   more..

^a Doctor Negrín University Hospital of Gran Canaria Las Palmas GC   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL SIERRALLANA   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g UNIDAD DE INVESTIGACIÓN   (Spain)

^h Dr Negrin University Hospital   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^j Universidad Pública de Navarra   (Spain)

^k HOSPITAL DONOSTIA   (Spain)

^l HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^m Rheumatology Department Lucus Augusti   (Spain)

ⁿ HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^o HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^p Ourense Hospital Complex   (Spain)

^q Alicante General Hospital   (Spain)

^r HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^s HOSPITAL JUAN CANALEJO   (Spain)

^t Guadalajara Hospital   (Spain)

^u Leon Hospital   (Spain)

^v HOSPITAL SON LLÀTZER   (Spain)

^w HOSPITAL RAMÓN Y CAJAL   (Spain)

^x HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^y HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^z HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^aa HOSPITAL DE BASURTO   (Spain)

^ab HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^ac Rheumatology Department Tenerife Clinic Hospital   (Spain)

^ad HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^ae H Jerez de la Frontera   (Spain)

^af HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^ag HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^ah HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^ai Hospitalet   (Spain)

^aj Rheumatology Unit L'Alt Penedés District Hospital   (Spain)

^ak HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^al Hospital Parc Tauli   (Spain)

^am HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^an Centro Integral Oncológico Clara Campal HM CIOCC   (Spain)

^ao HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^ap Hospital de Monforte   (Spain)

^aq Hospital and University Complex   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ADULT; ALOPECIA; ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE REGISTRY; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITALIZATION; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIPHERAL VASCULAR DISEASE; PLASMAPHERESIS; PRIORITY JOURNAL; RETINOPATHY; SEIZURE; SKIN ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS; CLINICAL TRIAL; COMPARATIVE STUDY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTICENTER STUDY; REGISTER; SPAIN;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; REGISTRIES; SPAIN;

EID: 84921395669     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000267     Document Type: Article

References (39)

1. Bertoli M, Alarcón GS. Epidemiology of systemic lupus erythematosus. In: Tsokos GC, Gordon C, Smolen JS, eds. Systemic Lupus Erythematosus, a Companion to Rheumatology. 1st ed Philadelphia, PA: Mosby-Elsevier; 2007:1-18
2. Sociedad Española De Reumatología. Estudio EPISER: Prevalencia De las enfermedades reumáticas en la población española. España: Merck Sharp & Done Ed; 2001
3. Carmona L, Ballina FJ, Gabriel R, et al., EPISER Study Group. The burden of musculoeskeletal diseases in the general population of Spain: results from a nationwide study. Ann Rheum Dis. 2001;60:1040-1045
4. Villa-Blanco I, Calvo-Alén J. Utilizing registries in systemic lupus erythematosus clinical research. Expert Rev Clin Immunol. 2012;8:353-360
5. Bertsias G, Ioannidis JP, Boletis J, et al., Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67:195-205
6. Ståhl Hallengren C, Nived O, Sturfelt G. Outcome of incomplete systemic lupus erythematosus after 10 years. Lupus. 2004;13:85-88
7. Swaa AJ, van De Brink H, Smeenk RJ, et al. Incomplete Systemic Lupus Erythematosus: results from a multicentric study under supervision of EULAR Standing Committee on International Clinical Studies including Therapeutic Trials (ESCISIT). Rheumatol. 2001;40:89-94
8. Vilá LM, Mayor AM, Valentín AH, et al. Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. Lupus. 2000;9:110-115
9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725
10. Rúa-Figueroa I, López-Longo FJ, Calvo-Alén J, et al., Grupo De trabajo en Enfermedades Autoinmunes Sistémicas De la Sociedad Española De Reumatología (EAS-SER); Unidad De Investigación De la Sociedad Española De Reumatología (UI-SER). National registry of patients with systemic lupus erythematosus of the Spanish Rheumatology Society: objectives and methodology. Reumatol Clin. 2014;10:17-24
11. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-1277
12. Hawker G, Gabriel S, Bombardier C, et al. A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. J Rheumatol. 1993;20:657-660
13. Symmons DPM, Coppock JS, Bacon PA, et al. Development of a computerised index of clinical disease activity in systemic lupus erythematosus. Q J Med. 1988;69:927-937
14. Yee CS, Farewell V, Isenberg DA, et al., British Isles Lupus Assessment Group. Revised British Isles Lupus Assessment Group 2004 Index. A reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum. 2006;54:3300-3305
15. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363-369
16. Petri M, Kim MY, Kalunian KC, et al., OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Eng J Med. 2005;353:2550-2558
17. Katz JD, Senecal JL, Rivest C, et al. A simple severity of disease index for systemic lupus erythematosus. Lupus. 1993;2:119-123
18. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306
19. Alarcón-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for Mixed Connective tissue Disease. Study of 593 patients. J Rheumatol. 1989;16:328-334
20. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619
21. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. [2013 version]. Available in: http://www.wma.net/en/20activities/10ethics/10helsinki
22. Convenio para la protección De los derechos humanos y la dignidad del ser humano con respecto a las aplicaciones De la biología y la medicina. Guía Internacional De la Bioética. Available in: http://www.bioeticas.net/leg/001.htm
23. Ley Orgánica 15/1999 De 13 De diciembre De Protección De Datos De Carácter Personal. Boletín Oficial del Estado 1999; núm.298, 43088-43099
24. Voss A, Green A, Junker P. Systemic lupus erythematosus in Denmark: clinical and epidemiological characterization of a countybased cohort. Scand J Rheumatol. 1998;27:98-105
25. Carreño L, López-Longo FJ, Monteagudo I, et al. Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. Lupus. 1999;8:287-292
26. Alarcón GS, McGwin G, Bertoli AM, et al., LUMINA Study Group. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66:1168-1172
27. Sabio JM, Vargas-Hitos JA, Navarrete-Navarrete N, et al., Grupo Lupus Virgen De las Nieves. Prevalence of and factors associated with hypertension in young and old woman with systemic lupus erythematosus. J Rheumatol. 2011;38:1026-1032
28. Ward MM, Studenski S. Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking. Arch Intern Med. 1992;10:2082-2088
29. Greer JM, Panush RS. Incomplete lupus erythematosus. Arch Intern Med. 1989;149:2473-2476
30. Olsen NJ, Yousif M, Mutwally A, et al. Organ damage in high-risk patients with systemic and incomplete lupus syndromes. Rheumatol Int. 2013;10:2585-2590
31. Instituto Nacional De Estadística. España en cifras 2013. Available in: http://www.ine.es/inebmenu/mnu-dinamicapob.htm
32. Cervera R, Khamashta MA, Font J, et al. The European Working Party for Systemic Lupus Erythematosus. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients. Medicine (Baltimore). 1993;72:113-124
33. Reveille JD, Moulds JM, Chulahn, et al., for the LUMINA study group. Systemic lupus erythematosus in three ethnic groups I. The effects of HLA Class 11, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. Arthritis Rheum. 1998;41:1161-1172
34. Pons-Estel BA, Catoggio LJ, Cardiel MH, et al., Grupo Latinoamericano De Estudio del Lupus. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among Hispanics"". Medicine (Baltimore). 2004;83:1-17
35. Cervera R, Khamashta MA, Hughes GR. The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus. 2009;18:869-874
36. Alarcon GS, Roseman J, Bartolucci AA, et al., for the LUMINA study group. Systemic Lupus Erythematosus in three ethnic groups. II Features Predictive of Disease Activity Early in Its Course. Arthritis Rheum. 1998;41:1177-1180
37. Arevalo JF, Lowder CY, Muci-Mendoza R. Ocular manifestations of systemic lupus erythematosus. Curr Opin Ophthalmol. 2002;13:404-410
38. Peponis V, Kyttaris VC, Tyradellis C, et al. Ocular manifestations of systemic lupus erythematosus: a clinical review. Lupus. 2006;15:3-12
39. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus. A multicenter prospective study of 1000 patients. Medicine (Baltimore). 1999;78:167-175